Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer [clinicaltrials:NCT00002947]
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer [clinicaltrials:NCT00002947]
Bio2RDF identifier
NCT00002947
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00002947
identifiers.org URI
anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Radiation th ...... s who have refractory cancer.
brief title [clinicaltrials_vocabulary:brief-title]
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2004-08-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES: I. Determin ...... ll be accrued for this study.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
1999-11-01T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
keyword [clinicaltrials_vocabulary:keyword]
WDHA syndrome
childhood Langerhans cell histiocytosis
ciliary body and choroid melanoma, medium/large size
extensive stage small cell lung cancer
extraocular extension melanoma
gastrinoma
glucagonoma
insulinoma
iris melanoma
metastatic gastrointestinal carcinoid tumor
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2014-07-01T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00002947
official title [clinicaltrials_vocabulary:official-title]
A Phase I Study of [111In-DTPA ...... ressing Somatostatin Receptors
org study id [clinicaltrials_vocabulary:org-study-id]
CDR0000065414
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2004-08-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
YALE-HIC-9041
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
1996-10-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2014-07-01T00:00:00Z
identifier
clinicaltrials:NCT00002947
title
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
@en
type
label
Indium In 111 Pentetreotide in ...... r [clinicaltrials:NCT00002947]
@en